EUVIMEDEUVIMED entdecken
Crossref

Aficamten is associated with improvements in cardiac mechanics in obstructive hypertrophic cardiomyopathy: Results from FOREST-HCM

Mei-Ling Chen, James Hodovan, Ahmad Masri, Victoria Liu, Mi-Ok Kim, Chiara Melloni, Daniel L Jacoby, Stephen B Heitner, Theodore P Abraham

Progress in Cardiovascular Diseases · 2026-08

DOI: 10.1016/j.pcad.2026.08.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Progress in Cardiovascular Diseases, 2026-08. Verfasst von Mei-Ling Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of California, 505 Parnassus Ave, San Francisco, CA 94143, USA; Changhua Christian Hospital, No. 135, Nanxiao St, Changhua City, Changhua …. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Cytokinetics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aficamten is a next-in-class, selective cardiac myosin inhibitor (CMI) that relieves left ventricular outflow tract (LVOT) obstruction in obstructive hypertrophic cardiomyopathy (oHCM) by addressing underlying myocardial hypercontractility. The long-term impact of aficamten on myocardial mechanics as measured by global longitudinal strain (GLS) is unknown. METHODS: FOREST-HCM (NCT04219826) is an ongoing open-label extension trial for eligible patients with HCM who completed a parent study of aficamten. Here we report echocardiographic parameters (LVOT gradient and myocardial GLS) obtained from baseline up to week 48 from oHCM patients (N = 27) included in the FOREST-HCM study. RESULTS: From baseline to 38 ± 4.8 weeks, aficamten reduced LVOT gradients at rest (mean difference - 32.7 ± 24 mmHg, p < 0.0001 vs. baseline) and with Valsalva (mean difference - 62.44 ± 34.5 mmHg, p < 0.0001 vs. baseline). Compared to baseline, strain analysis revealed similar GLS at week 12 (-13.9 ± 3.2 vs. -14.3 ± 3.0, p = 0.316) but a significant improvement at weeks 36-48 (-13.9 ± 3.2 vs. -15.1 ± 2.7, p = 0.0093). These improvements were only seen in patients who achieved a hemodynamic response (resting LVOT-G < 30 mmHg, n = 24, p = 0.0009; or complete response with rest

Schlagwörter

Stichwörter der Autor:innen

AficamtenGlobal longitudinal strainObstructive hypertrophic cardiomyopathy

Autor:innen und Institutionen

  • University of California, 505 Parnassus Ave, San Francisco, CA 94143, USA; Changhua Christian Hospital, No. 135, Nanxiao St, Changhua City, Changhua County 500, Taiwan.
  • Oregon Health & Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: hodovan@ohsu.edu.
  • Oregon Health & Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: masria@ohsu.edu.
  • University of California, 505 Parnassus Ave, San Francisco, CA 94143, USA. Electronic address: victoria.liu2@ucsf.edu.
  • University of California, 505 Parnassus Ave, San Francisco, CA 94143, USA.
  • Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, CA 94080, USA. Electronic address: cmelloni@cytokinetics.com.

Förderung

  • Cytokinetics

Zitieren

APA

Chen, M. L., Hodovan, J., Masri, A., Liu, V., Kim, M. O., Melloni, C., Jacoby, D. L., Heitner, S. B., & Abraham, T. P. (2026). Aficamten is associated with improvements in cardiac mechanics in obstructive hypertrophic cardiomyopathy: Results from FOREST-HCM. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2026.08.013

Vancouver

Chen ML, Hodovan J, Masri A, Liu V, Kim MO, Melloni C, et al. Aficamten is associated with improvements in cardiac mechanics in obstructive hypertrophic cardiomyopathy: Results from FOREST-HCM. Progress in Cardiovascular Diseases. 2026. doi:10.1016/j.pcad.2026.08.013

BibTeX
@article{Chen2026,
  author = {Chen, Mei-Ling and Hodovan, James and Masri, Ahmad and Liu, Victoria and Kim, Mi-Ok and Melloni, Chiara and Jacoby, Daniel L and Heitner, Stephen B and Abraham, Theodore P},
  title = {Aficamten is associated with improvements in cardiac mechanics in obstructive hypertrophic cardiomyopathy: Results from FOREST-HCM},
  journal = {Progress in Cardiovascular Diseases},
  year = {2026},
  doi = {10.1016/j.pcad.2026.08.013}
}
Kostenlos starten →